NYSE:CBM - Cambrex Stock Price, News, & Analysis

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) posted its quarterly earnings results on Wednesday, February, 13th. The biotechnology company reported $1.44 EPS for the quarter, beating the Zacks' consensus estimate of $1.32 by $0.12. The biotechnology company earned $212.30 million during the quarter, compared to analyst estimates of $182.49 million. Cambrex had a net margin of 17.37% and a return on equity of 14.74%. The firm's revenue was up 16.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.26 EPS. View Cambrex's Earnings History.

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Cambrex.

Cambrex issued an update on its FY19 earnings guidance on Wednesday, February, 13th. The company provided EPS guidance of $1.87-2.09 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.18. Cambrex also updated its FY 2019 guidance to $1.87-2.09 EPS.

4 equities research analysts have issued 12 month target prices for Cambrex's shares. Their forecasts range from $45.00 to $75.50. On average, they anticipate Cambrex's share price to reach $61.1667 in the next year. This suggests a possible upside of 59.8% from the stock's current price. View Analyst Price Targets for Cambrex.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

Media stories about CBM stock have been trending neutral on Wednesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cambrex earned a daily sentiment score of 0.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days.

Some companies that are related to Cambrex include Array Biopharma (ARRY), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Intercept Pharmaceuticals (ICPT), Ascendis Pharma A/S (ASND) and ACADIA Pharmaceuticals (ACAD).

Cambrex's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.56%), Bank of New York Mellon Corp (4.93%), Mackenzie Financial Corp (4.43%), Dimensional Fund Advisors LP (4.20%), American Capital Management Inc. (1.99%) and Ranger Investment Management L.P. (1.96%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Acadian Asset Management LLC, Investment Counselors of Maryland LLC, LSV Asset Management, American Capital Management Inc., New York State Common Retirement Fund, Barclays PLC and Portolan Capital Management LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.

CBM stock was purchased by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, Copper Rock Capital Partners LLC, BlackRock Inc., Bank of New York Mellon Corp, Epoch Investment Partners Inc., Monarch Partners Asset Management LLC, Peregrine Capital Management LLC and Bank of America Corp DE. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $38.27.

Cambrex has a market capitalization of $1.29 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.

The official website for Cambrex is http://www.cambrex.com.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]